Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up

Journal of Pathology

Volumn 186, Issue 2, 1998, Pages 157-164

  Lipponen, P ^a   Aaltoma, S ^b   Kosma, V M ^a,b   Ala Opas, M ^b   Eskelinen, M ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bladder cancer; CD44s; CD44v6; Prognosis

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER TUMOR; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0031670939     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(1998100)186:2<157::AID-PATH169>3.0.CO;2-M     Document Type: Article

References (32)

1. Jalkanen S, Bargatze RF, De Los Toyos J, Butcher EC. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph-node, mucosal, or synovial endothelial cells. J Cell Biol 1987; 105: 983-990.
2. Lesley J, Hyman R, Kinkade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993; 54: 271-335.
3. Haynes B, Telen M, Hale L, Denning S. CD44 - a molecule involved in leucocyte adherence and T-cell activation, Immunol Today 1989; 10: 423-428.
4. Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. J Clin Pathol: Mol Pathol 1997; 50: 57-71.
5. Screaton GR, Bell MV, Jackson DG, Cornells FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-12164.
6. Gunthert U, Hofman M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
7. Mackay CR, Terpe H-J, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994; 124: 71-82.
8. Heider KH, Dammrich J, Skroch-Angel P, et al. Differential expression of CD44 splice variants in intestinal and diffuse-type human gastric mucosa. Cancer Res 1993; 53: 4197-4203.
9. Ropponen K, Eskelinen M, Lipponen P, Alhava E, Kosma V-M. Expression of CD44 and variant proteins in human colorectal cancer and its relevance to prognosis. Scand J Gastroenterol (in press).
10. Mulder JW, Kruyt P, Sewnath M, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994; 26: 1470-1471.
11. Wielenga VJ, Heider K, Offerhaus JA, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumour progression. Cancer Res 1993; 53: 4754-4756.
12. Koopman G, Heider KH, Horst E, et al. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis associated variant of CD44 . J Exp Med 1993; 177: 897-904.
13. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993; 143: 687-874.
14. Washington MK, Gottfried MR, Telen MJ. Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Lab Invest 1993; 68: 52A.
15. Charpin C, Garcia S, Bouvier C, et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 1997; 28: 289-296.
16. Soukka T, Salmi M, Joensuu H, et al. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 1997; 57: 2281-2289.
17. Hong R-L, Pu Y-S, Hsieh T-S, Chu J-S, Lee W-J. Expression of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 1995; 153: 2025-2028.
18. Ross JS, Rosario AD, Bui HX, Kallakury BVS, Okby NT, Figge J. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol 1996; 9: 854-860.
19. Southgate J, Trejdosiewicz LK, Smith B, Selby PJ. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer 1995; 62: 449-456.
20. Woodman AC, Sugiyama M, Yoshida K, et al. Analysis of anomalous CD44 gene expression in human breast, bladder and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 1996; 149: 1519-1530.
21. Sugino T, Gorham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 1996; 149: 873-882.
22. Zingg EJ, Wallace DMA. Bladder Cancer. Heidelberg: Springer-Verlag, 1985: 1-21, 161-191.
23. International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. Geneva: UICC, 1978.
24. Mostofi FK International histological classification of tumours. In: No 10 Histological Typing of Urinary Bladder Tumours. Geneva: WHO, 1973.
25. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 1993; 29A: 69-75.
26. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R, Haapasalo H. Independent clinical, histological and quantitative prognostic factors in transitional-cell bladder tumours, with special reference to mitotic frequency. Int J Cancer 1992; 51: 396-403.
27. Lipponen PK, Nordling S, Eskelinen MJ, Jauhiainen K, Terho R, Harju E. Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int J Cancer 1993; 53: 42-47.
28. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69: 1120-1125.
29. Lipponen PK, Eskelinen MJ, Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. Cancer Res Clin Oncol 1995; 121: 303-308.
30. Abbasi AM, Chester KA, Talbot IC, et al. CD44 is associated with proliferation in normal and neoplastic human colorectal epithelium. Eur J Cancer 1993; 29: 1995-2002.
31. Friedrichs K, Kugler G, Franke F, et al. CD44 isoforms in prognosis of breast cancer. Lancet 1995; 345: 1237.
32. Piffko J, Bankfalvi Å, Klauke K, et al. Unaltered strong immunohistochemical expression of CD44-v6 and -v5 isoforms during development and progression of oral squamouscell carcinomas. J Oral Pathol Med 1996; 25: 502-506.